2.61
-0.01(-0.38%)
Currency In USD
| Previous Close | 2.62 |
| Open | 2.65 |
| Day High | 2.76 |
| Day Low | 2.61 |
| 52-Week High | 6.2 |
| 52-Week Low | 1.33 |
| Volume | 97,329 |
| Average Volume | 1.68M |
| Market Cap | 24.87M |
| PE | -2.12 |
| EPS | -1.23 |
| Moving Average 50 Days | 2.62 |
| Moving Average 200 Days | 2.52 |
| Change | -0.01 |
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children a
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
GlobeNewswire Inc.
Jun 10, 2025 12:00 PM GMT
Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBSNeurAxis’s PENFS technology is the only FDA-cle
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children an